Hypertension in women has received less attention than hypertension in men, and the major controlled trials of antihypertensive therapy have been carried out in populations made up predominantly of and have emphasised outcomes in men. Recently it has been recognised that women develop high blood pressure, particularly systolic hypertension, at an increased rate as they age, and that this age-related blood pressure increase is exaggerated by the menopause. The age-related rise in blood pressure, particularly systolic blood pressure and pulse pressure, contributes substantially to the age-related increase in risk of heart attack, heart failure, and stroke in middle-aged and elderly women. This article reviews
Introduction
Despite its high prevalence in the population, hypertension in women has received less attention than hypertension in men. [1] [2] [3] The major controlled trials of antihypertensive therapy have been carried out in populations made up predominantly of men and have emphasised outcomes in men. Recently it has been recognised that women develop high blood pressure, particularly systolic hypertension, at an increased rate as they age, and that this age-related blood pressure increase is exaggerated by the menopause. The age-related rise in blood pressure, particularly systolic blood pressure and pulse pressure, contributes substantially to the age-related increase in risk of heart attack, heart failure, and stroke in middle-aged and elderly women. 2 Two unique hypertension-inducing mechanisms-pregnancy and the use of oral contraceptives-also contribute to the global problem of high blood pressure in women. The pathophysiology of hypertension in women differs in other ways from that in menwomen tend to have more labile blood pressures and a higher prevalence of the white coat phenomenon. 4, 5 Women are more likely to be salt-sensitive; and are more likely to have low renin, high volume hypertension than men. 6 This section will review aspects of hypertension epidemiology, pathophysiology, diagnosis and treat-aspects of hypertension epidemiology, pathophysiology, diagnosis and treatment that are important to women's health with particular emphasis on important concomitant cardiovascular disease risk factors such as type 2 diabetes and the menopause. The role of ovarian hormones and their withdrawal in the pathogenesis of hypertension and related target organ damage is considered, as are the results of drug treatment of high blood pressure in women. Blood pressure in pregnancy is discussed in a separate article by Broughton-Pipkin and Roberts. Journal of Human Hypertension (2000) 14, [691] [692] [693] [694] [695] [696] [697] [698] [699] [700] [701] [702] [703] [704] ment that are important to women's health with particular emphasis on important concomitant cardiovascular disease risk factors such as type 2 diabetes and the menopause. The role of ovarian hormones and their withdrawal in the pathogenesis of hypertension and related target organ damage will be considered, as will the results of drug treatment of high blood pressure in women.
Epidemiology
Blood pressure development exhibits a sexually dimorphic pattern in human populations. 1 Gender differences in blood pressure emerge during adolescence and persist through adulthood. 7, 8 In all ethnic groups, younger men tend to have higher mean systolic and diastolic blood pressure than younger women (by 6-7 mm Hg and 3-5 mm Hg respectively), and through middle age, hypertension is more prevalent among men than women ( Figure  1 ). 9 However, hypertension is more prevalent among women than men after age 59. Whether there is a 'crossover' in the relative prevalence of hypertension in men vs women, with younger men and older women having more hypertension, is a point of controversy. A crossover was reported in a number of cross-sectional studies, 10 but was not apparent in the 30-year longitudinal data from Framingham. 11 Mean systolic blood pressure in older women in Framingham approached but did not exceed that of older men; mean diastolic was lower in women at all ages, and declined in both sexes after age 65 .
The influence of menopause on blood pressure in women is also a matter of controversy. Longitudinal studies from Framingham, 12 Allegheny County, 13 and the Netherlands, 14 did not document a rise in blood pressure with menopause. In contrast, crosssectional studies from Belgium 15 and the US 16 found significantly higher systolic and diastolic blood pressure in postmenopausal compared to premenopausal women. Staessen et al 15 reported a four-fold higher prevalence of hypertension in postmenopausal women than in premenopausal women (40% vs 10%, P Ͻ 0.001). After adjusting for age and body mass index, postmenopausal women were still more than twice as likely to have hypertension as premenopausal women. 15 In a more recent prospective evaluation of conventional and ambulatory blood pressure in women who were pre-, peri-, and postmenopausal, the postmenopausal women had higher systolic blood pressure (4 -5 mm Hg, P р 0.05) compared to their pre-and perimenopausal controls. The rise in systolic blood pressure per decade was 5 mm Hg greater in the peri-and postmenopausal women than the premenopausal group (P р 0.05) ( Figure 2 ). 17 Thus, there is conflict between longitudinal and cross-sectional studies, both of which are vulnerable to confounding variables, but there is convincing evidence that at least a portion of the rise in blood pressure (particularly systolic blood pressure) seen later in life in women is due to menopause and its effects on the female hormonal milieu. 18
Pathophysiology
Sex hormones and/or their removal from the endocrine milieu may alter blood pressure by a variety of mechanisms and thus contribute to the wide pulse pressure and higher prevalence of isolated systolic hypertension seen in older women. Proximal aortic stiffness has been associated with coronary heart disease, 19, 20 and there is evidence that oestrogen directly affects systemic arterial compliance. 21 Oestrogen affects the expression of the reninangiotensin system and the level of plasma catecholamines-both of which may play important roles in the pathogenesis of essential hypertension. Oestrogen clearly elevates angiotensinogen gene expression and serum levels of angiotensinogen. 22 The effect on renin levels is less clear, largely because of difficulties in measuring renin protein levels directly. 23 Shunkert et al 24 used an immunoradiometric assay with a monoclonal antibody to assess renin levels in postmenopausal women with and without hormone replacement therapy. There were no differences in blood pressure between the groups, but renin levels were lower in women receiving oral or transdermal oestrogen (12.0 ± 0.7 mU/L) than in women not receiving oestrogen (16.6 ± 0.9 mU/L; P Ͻ 0.001). 24 Plasma noradrenaline levels provide a clinically useful index of sympathetic nervous system activity in human subjects. 25, 26 Villecco et al 27 used a headup tilt test as a physiological stimulus to study blood pressure, heart rate, and plasma noradrenaline in women. They demonstrated that hypertensive women (both pre-and postmenopausal) had a significantly greater increase in noradrenaline secretion after physiological stimulation than normotensive women (P Ͻ 0.01) ( Figure 3 ). The greatest changes in noradrenaline values above baseline levels were seen in the postmenopausal group. 27 Endothelial function deteriorates with aging in both men and women, but there is evidence that this aging change is accelerated in women following the withdrawal of ovarian hormones. Taddei et al 28 used intrabrachial acetylcholine and brachial artery plethysmography to investigate endothelium-dependent vasodilation in normotensive and hypertensive men and women. They studied 73 normotensive subjects (37 women and 36 men) and 73 hypertensive subjects (36 women and 37 men) by injecting intrabrachial acetylcholine and measuring the effects on forearm blood flow. The response to acetylcholine had a strong negative correlation with age in hypertensive as well as control subjects. Further, in hypertensive men and women there was a change-point in the age-related decrement in response to acetylcholine-and, therefore, a decrease in endothelium-dependent vasodilation ( Figure 4 ). Prior to this change-point (age 40 in males and age 49 in females), the age-related decline in response to acetylcholine was more rapid in men than women (2.1%/yr vs 1.3%/yr; P Ͻ 0.01), while after the change-point, the rate of decline slowed in men and accelerated in women (1.3%/yr vs 2.8%/yr; Figure 4 Age-related decrease in forearm blood flow response in hypertensive patients. 28 Journal of Human Hypertension P Ͻ 0.02). This finding, at an age typical of the onset of menopause, in women is highly suggestive of a process related to sex hormones and their effects on vascular endothelial function.
There is also an age and/or sex hormone dependent dimorphism in the sensitivity of blood pressure to dietary NaCl. Elderly (postmenopausal) women appear to be more NaCl-sensitive than age-matched men. [29] [30] [31] A study carried out in postmenopausal Japanese women showed that NaCl sensitivity correlated inversely with levels of circulating ovarian hormones. 31 Comparison of blood pressure responses to high and low NaCl diets in hypertensive postmenopausal women vs age-matched, normotensive postmenopausal women showed that eight of 12 hypertensive women, but only one of seven normotensive subjects were NaCl sensitive. These data support the hypothesis that decreases in sex hormones and increased sensitivity to dietary NaCl are important factors in the genesis of postmenopausal hypertension.
These mechanisms offer several possible explanations for elevated blood pressure after menopause. Concomitant age-related physiological changes also contribute to blood pressure elevation and the development of hypertension in older (postmenopausal) women and men. For example, blood pressure increases with age and body weight independent of the menopause. More investigation is needed before the relative contributions of aging and the menopause to the pathogenesis of hypertension in older women can be fully assessed.
Postmenopausal hormone replacement therapy and blood pressure

Normotensive women
Unlike oral contraceptives, which tend to increase blood pressure in all women and can cause frank hypertension in a small percentage, the conjugated and natural oestrogens used for postmenopausal replacement therapy are administered at doses that result in 'physiologic' levels of circulating oestrogen. These doses and formulations of oestrogen do not appear to cause hypertension, or even a tendency for blood pressure elevation. Prospective studies have shown that administration of conjugated and natural oestrogens, alone or in combination with a progestin, to normotensive postmenopausal women generally has no effect on blood pressure or tends to reduce it.
The Postmenopausal Estrogen/Progestin Interventions Trial (PEPI) evaluated cardiovascular risk factors in 875 normotensive postmenopausal women aged 45-64 years randomly assigned to treatment with a variety of different regimens of hormone replacement therapy, including conjugated equine oestrogen alone or in combination with a variety of progestins. 32 After 3 years of follow-up, there were no differences in systolic or diastolic blood pressure in any treatment group compared to placebo ( Figure 5 ). In contrast to these results with conjugated equine oestrogen, studies of the effects of 17␤-estradiol in normotensive postmenopausal Journal of Human Hypertension Figure 5 Effect of conjugated oestrogens and progesterone on blood pressure in normotensive postmenopausal women. 32 women have revealed a tendency to reduce blood pressure. [33] [34] [35] [36] Cagnacci et al 33 evaluated the effects of 2 months of transdermal oestrogen (50 g/day) on 24-h ambulatory blood pressure in normotensive postmenopausal women. Night-time systolic, diastolic, and mean blood pressures were all significantly reduced in women receiving oestrogen compared with placebo, while there was no difference between groups in daytime blood pressure.
Seely et al 34 evaluated the effects of transdermal estradiol (two 0.1 mg patches administered twice weekly) and intravaginal progesterone (300 mg nightly) on 24-h ambulatory blood pressure in healthy postmenopausal women. These doses of oestrogen and progesterone provided physiologic premenopausal levels of circulating oestrogen and progesterone. As in the Cagnacci study, night-time systolic, diastolic, and mean blood pressures were significantly lower in both estradiol and estradiol/progesterone treated women compared to placebo. There were trends toward lower daytime systolic and diastolic blood pressures in patients on estradiol or estradiol/progesterone compared to placebo, but only the daytime mean blood pressure of the estradiol group was significantly less than placebo. Similar to the data from the PEPI trial, there were no differences in office blood pressure measurements between women treated with hormones compared to placebo.
PEPI used conjugated equine oestrogen, which may have different effects from estradiol, and did not utilise ambulatory blood pressure monitors, nor did it evaluate night-time blood pressures. Since there is evidence that women may be particularly vulnerable to white coat hypertension 5 and that nocturnal blood pressure may be more sensitive than diurnal blood pressure to the effects of postmenopausal hormone replacement therapy, there is reason to believe that some subtle but potentially important effects of hormone replacement therapy on blood pressure may have been missed in PEPI.
Other studies of transdermal estradiol in healthy women utilising 24-h blood pressure data yielded similar results. Chronic transdermal oestrogen administered in a non-randomised, non-placebocontrolled fashion lowered nocturnal blood pressure, 35 and administration of 17␤-estradiol with either 5 or 10 mg of the progestin dydrogesterone (days 14 -28) lowered 24-h ambulatory blood pressure after 12 months of therapy. 36 It is, therefore, well-established that administration of oral conjugated oestrogen or oral or transdermal estradiol, alone or in combination with a progestin, to normotensive postmenopausal women has either neutral effects or tends to reduce blood pressure.
Hypertensive women
While no large, prospective trials have evaluated hormone replacement in hypertensive women, a growing body of smaller trials indicate that hormone replacement has a neutral effect or lowers blood pressure in postmenopausal women. Lip, Beevers et al 37 followed 75 hypertensive postmenopausal women on hormone replacement therapy for 36 months and found no significant increase in blood pressure. Manhem et al 38 found a modest, 3 mm Hg reduction in daytime blood pressure in hypertensive women who were given transdermal oestrogen. Further, Mercuro et al 39 followed ambulatory blood pressure in 30 postmenopausal women with mild hypertension while they were treated with transdermal oestrogen. The subjects were divided into two groups on the basis of the presence or absence of a Ͼ10% drop in night-time blood pressure with respect to daytime blood pressure ('dippers vs nondippers'). Both groups showed significant decreases in systolic and diastolic blood pressure ( Figure 6 ) while on oestrogen therapy. Therefore, though there are no large prospective studies, data from several populations indicate that hormone replacement therapy does not elevate-and may lower-blood pressure in hypertensive women. Thus, it is currently recommended that all hypertensive women treated with postmenopausal hormone replacement therapy have their blood pressure measured at 3-6 month intervals.
Postmenopausal hormone replacement therapy and vascular compliance
Studies of arterial compliance in postmenopausal women have provided a novel rationale for the use Figure 6 Hourly mean blood pressure in hypertensive postmenopausal women. 39 of hormone replacement therapy. [40] [41] [42] [43] Arterial stiffness as determined by pulse wave velocity increases with age in both sexes, but this increase is greatly accelerated in women in the perimenopausal period. 40 As a consequence, the gender difference in arterial compliance (premenopausal women Ͼ agematched men) disappears in the postmenopausal years. This may be reflected in a perimenopausal increase in pulse pressure, a surrogate measure of arterial stiffness and a powerful independent predictor of subsequent coronary events. 41 The rapid decline in arterial compliance in perimenopausal hypertensive women is related to a fall in endogenous oestrogen levels, leading to studies of the role of hormone replacement therapy in modulating arterial stiffness/compliance in postmenopausal women. 42 Short-term administration of oestrogens has been shown to reduce aortic stiffness in postmenopausal women, while long-term use of the synthetic steroid Tibolone, which is structurally related to norethisterone, did not alter compliance, as reflected in aortic pulse wave velocity. 43 The capacity of long-term (minimum 1.5 years; mean 7 years) administration of hormone replacement therapy (oestrogen alone or oestrogen + progestin) to modify arterial compliance in postmenopausal women has been tested. 42 Control groups included postmenopausal women who were not receiving hormone replacement therapy and younger pre-Journal of Human Hypertension menopausal women. Total systemic arterial compliance was estimated by measurement of aortic flow using continuous wave Doppler velocimetry with simultaneous carotid pressure waveform recording; pulse wave velocity, by applanation tonometry. All participants were free of clinical cardiovascular disease. Systemic arterial compliance was greatly reduced in the untreated postmenopausal group compared to both the premenopausal and the hormone-treated groups (Figure 7 ). Women receiving both oestrogen and progestin replacement showed a statistically nonsignificant trend toward greater improvement in arterial compliance than women receiving oestrogen alone, reaching levels not significantly different from those in premenopausal women. Mean pulse wave velocity over the aortofemoral region was significantly reduced in the hormone treated group as a whole compared to the untreated postmenopausal group. Central pulse pressure was elevated in the untreated postmenopausal group (56 ± 4 mm Hg) compared to both the hormone treated (45 ± 3 mm Hg) and premenopausal (43 ± 1 mm Hg) groups. This was not reflected in differences between postmenopausal groups in systolic, diastolic, or pulse pressure in the periphery, in cardiac output, or in total peripheral resistance.
A follow-up study from the same group examined the effects of withdrawal and reinstitution of hormone therapy, each for 4 weeks, on arterial compliance in postmenopausal women who had previously taken long-term hormonal therapy. 44 Significant decreases in systemic arterial compliance and increases in femoral dorsalis pedis pulse wave velocity were observed following withdrawal of hormone therapy; these parameters returned to baseline values within 4 weeks of reinstituting hormones. The rapid time course of the reduction in arterial compliance after cessation of hormone replacement therapy and of the increase in compliance after reinstituting hormone treatment is more consistent with a vasodilator mechanism than with structural remodelling of the vessel wall, which would be expected to be a more lengthy process. 45 These findings are consistent with the transient nature (ie therapy must be continuous for benefit to be maintained) of the vasoprotective effects of postmenopausal hormone replacement therapy. 46 A more recent study evaluated systemic arterial compliance in 109 postmenopausal women receiving hormone replacement therapy compared with 108 age-matched untreated controls. Women receiving hormone replacement therapy had a higher systemic arterial compliance than controls (P Ͻ 0.0001). 47 These findings point to another mechanistic target for this therapeutic intervention.
Target organ effects
To reduce cardiovascular complications, hormone replacement therapy should induce regression of structural abnormalities in the heart and blood vessels, as well as reduce blood pressure. A few studies have specifically assessed target organ damage in hypertensive postmenopausal women and examined the efficacy of hormone replacement therapy in 48 evaluated hormone replacement therapy and its effects on left ventricular mass in hypertensive women. One hundred and sixty-nine postmenopausal women with controlled stage 1 and 2 hypertension were randomised to transdermal 17␤-estradiol (50 g/24 h patches) or placebo and underwent an M-mode and 2-D echocardiogram at baseline, and again at 6, 12, and 18 months after randomisation. There were no differences between treatment and placebo in the early phases of the study, but at 18 months, women receiving oestrogen had significantly reduced less left ventricular mass and left ventricular hypertrophy ( Figure 8 ). There were no differences in overall left ventricular cavity size or function as assessed by end-systolic and end-diastolic diameters and fractional shortening. This is one of the first pieces of evidence of a reduction in target organ damage associated with oestrogen therapy in hypertensive postmenopausal women. This effect may be related to the calcium antagonist effects of oestrogen 49 or an oestrogen-associated downregulation of the reninangiotensin system. 50
Oral contraceptive therapy and blood pressure
In contrast to postmenopausal hormone replacement therapy, oral contraceptive (OC) use is associated with increases in both blood pressure and cardiovascular disease events. The 1997 WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception reported an increased risk of acute myocardial infarction (AMI) among women who had known cardiovascular risk factors, including elevated blood pressure, and were taking combined OCs. 51 This study in 20 to 44-year-old women from Africa, Asia, Europe and Latin America found AMI extremely rare in non-smoking women on OCs who were under 35 years of age, and the risk fell lower yet when blood pressure was screened before, and presumably during OC use. The Nurses Health Study found that past use of OCs seemed to carry little or no risk of subsequent cardiovascular diseases. 52, 53 Reports on the effect of OCs on hypertension are mixed and difficult to compare for a number of reasons: many studies included few subjects and lacked appropriate controls; OC preparations changed over time, and differing combinations of oestrogen and progestogen which may act synergistically or antagonistically. 54 Following Woods' initial report 55 in 1967 of elevated blood pressure in hypertensive women on OCs, several investigators documented the considerable lowering of blood pressure among hypertensive women upon stopping OCs. [56] [57] [58] [59] [60] Laragh and Sealey 56 reported elevations in renin substrate concentration and aldosterone excretion, as well as abnormalities in renin activity and renin reactivity in women on OC therapy. Weinberger 57 also pointed out a rise in plasma renin substrate concentration in women on OC therapy. Hypertension induced by OCs has variously been attributed to activation of the renin angiotensin system, OC-induced sodium retention, elevated plasma volume and increased body weight. 61, 62 The incidence of hypertension in OC users varied greatly among early studies: from 4% 63 to 15.5%, 64 and 18%. 65 A 3-year study of 83 OC users 58 found increases in both systolic and diastolic blood pressures, 9.2 and 5.0 mm Hg, respectively, and a year later a smaller group of these women had a mean increase in systolic pressure of 14.2 mm Hg and in diastolic pressure of 8.5 mm Hg. Within 3 months of stopping OC therapy, the blood pressure returned to pretreatment levels. Both diastolic and systolic blood pressure rose among OC users in a study among urban women in Germany, 59 and fell in those stopping OCs. Interestingly, in the African-American community in southeastern United States, there were no differences in blood pressure changes associated with either orthostatic or mental challenge among users and non-users of OCs. 66 In a longitudinal study of 13 358 women on OCs, 60 there was a slight but statistically significant rise in mean blood pressure, which could be reversed with cessation of Journal of Human Hypertension therapy. The observation that oral contraceptive use is associated with blood pressure elevation has been validated with ambulatory blood pressure recording, the most accurate means of assessing blood pressure over time in free living individuals. 67 The association between elevated blood pressure, even slight, and the development of coronary artery disease has been emphasised by Kannel and Sorlie. 68 Thus, even a small rise in blood pressure during OC use appears to be pathophysiologically significant.
In general, the synthetic oestrogens and progestins used in OCs are administered in doses sufficient to suppress pituitary function, generally 4 -10 times the doses used in postmenopausal hormone replacement. Further, the synthetic oestrogens commonly used in oral contraceptives, eg ethinyl estradiol, have a greater ability to stimulate hepatic synthesis of angiotensinogen and induce sodium and fluid retention than the natural oestrogens used in hormone replacement therapy, thus accounting for the divergent haemodynamic effects of the two forms of hormone treatment. However, the magnitude of the blood pressure increase associated with OC use varies substantially depending on the oestrogen and progestin content of the preparation. Briggs and Briggs 69 reported no rise in blood pressure in women taking a 30 g oestrogen OC for 3 years, while there was an increase in those on a 50 g OC. In another study, blood pressure fell in hypertensive women when their 50 g oestrogen pill was changed to 30 g oestrogen. 58 Contrasting findings were reported in a study, 70 in which 15 women on 30 g oestrogen OCs registered higher blood pressures than 28 women on 50 g OCs-findings attributed by the authors to the different progestogenic components. Low-dose OCs were deemed so safe following a study of women of mean age 26.3 years after 6 and 12 months of use, that the authors considered they could be safely sold over the counter. 71 Taking them, they stated, 'does not place a patient in any high risk category'. 71 When a very small dosage of contraceptives was used in a 3-year study of 1000 women, there was no evidence of hypertension in any of the women, including those with a prior history of toxaemia. 72 The question of which component of the OC accounts for the rise in blood pressure was addressed by Khaw and Peart 73 in a study of two routinely prescribed OCs-Microgynon 30 and Eugynon 30. Each contained the same oestrogen dose-30 g ethinyloestradiol-and differed in progestogen: 150 g levonororgestrel in the former and 250 g levonororgestrel in the latter. A dose-related response of blood pressure to the progestogen component was observed, a finding that contradicted the generally held view that it is the oestrogen component that is responsible for the rise in blood pressure.
Although only a small percentage of OC users experience the onset of frank hypertension, and even fewer suffer from accelerated or malignant hypertension, OC-induced hypertension is still the most important and likely the most frequent form of secondary hypertension in younger women. 74 The Nurses' Health Study found that current users of
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OCs had significantly increased (relative risk (RR) = 1.8; 95% confidence interval (CI) = 1.5-2.3) risk of hypertension compared with never users (Table 1) . 75 Absolute risk was small: only 41.5 cases of hypertension/10 000 person-years could be attributed to OC use. The current risk of OC-induced hypertension is likely lower than reported in the earlier literature because oral contraceptives currently in use contain lower doses of ethinyl estradiol (30-35 mcg) than those previously used and there appears to be a correlation between both oestrogen and progestin dose and blood pressure in OC users. Nevertheless, data from the Nurses' Health Study II suggest that even OCs with lower doses of oestrogen increase the risk of hypertension, and that the risk increases with duration of use and with increased progestin potency.
Risk of hypertension decreases quickly with cessation of contraceptive use: past users have only a slightly increased risk (RR = 1.2; 95% CI = 1.0-1.4) compared to never users. Blood pressure generally returns to pretreatment levels within 3 months of discontinuing OCs, indicating that their blood pressure effect is relatively acute and readily reversible. Genetic characteristics, such as family history of hypertension, as well as environmental characteristics, including pre-existing pregnancy-induced hypertension, occult renal disease, obesity, middle age (Ͼ35 years), and duration of OC use, increase susceptibility to OC-induced hypertension.
A family history of hypertension and a personal history of renal disease, or of pregnancy-induced hypertension, are relative contraindications to OC use. Women over 35 years of age, particularly if obese, should be cautioned about the risk of developing hypertension while taking OCs and should be followed closely and their blood pressures measured on several occasions during the first year of treatment and annually thereafter. Contraceptive-induced hypertension can be diagnosed by documenting the onset of hypertension de novo during contraceptive therapy, along with resolution of the hypertension on drug withdrawal. The risk of hypertension is greater among users of monophasic combination OCs than among users of biphasic or triphasic combinations, perhaps because the total dose of progestin delivered is greater with the monophasic preparation. Cardiovascular risk status should be assessed in all women who are considering using OCs. 76 Specifically, women with a family history of premature heart disease should have lipid analysis before taking OCs; women at high risk for diabetes should have glucose testing before taking OCs; and women who develop hypertension while taking OCs should be advised to discontinue them. A prudent approach to OC use is to monitor blood pressure at least every 6 months (only dispense 6 months of pills). If blood pressure rises, then a decision to discontinue the OCs should be based on the degree of hypertension, the potential hazards of pregnancy, and overall cardiovascular risk profile. Although it is preferable to avoid OCs in individuals with elevated blood pressure, with careful monitoring of selected individuals, this modality of contraception can be considered when the risks of pregnancy appear greater than the risks of mild hypertension.
Contraceptives and disturbances in glucose metabolism
The relationship between OC use and glucose intolerance/insulin resistance is controversial. A review of large epidemiologic studies found no difference in the frequency of diabetes between users and non-users of high-dose OCs, while data from smaller studies revealed a two-fold increased risk of impaired glucose tolerance in current high-dose OC users compared to non-users. 77 Women (22-44 years old) treated with low-dose OCs and studied with an oral glucose tolerance test 78 showed a reduction in glucose tolerance (15.4% of users had impaired glucose tolerance vs only 6.3% of non-users). The impact of combined OCs on glucose tolerance and insulin and C-peptide concentrations has been attributed to a combination of oestrogen-induced insulin resistance and progestin-induced alterations in insulin half-life. 79 When the effects on the level of haemoglobin A 1c of a combined OC were compared with those of a progestin-only OC, 80 the former effected no change while the latter caused a significant rise in haemoglobin A 1c from 5.8% to 8.7%. Such studies must be treated with caution, however, since only biochemical effects of the OCs were observed, and diabetes did not develop in any of the patients. The reported impact of OCs on insulin resistance is also limited to biochemical changes; clinical sequelae have not been reported.
Use of newer OCs that contain lower doses of oestrogens and alternative progestins has resulted in fewer metabolic side effects. 81, 82 Nevertheless, because of concerns about exacerbating glucose intolerance, women at high risk for diabetes should have glucose testing before taking OCs and diabetic women who are using OCs should have their fasting glucose levels monitored carefully, at least in the beginning of OC use. 81
Oral contraceptive-induced hypercholesterolaemia
The increased risk of cardiovascular disease from higher-dose OCs has been attributed to a combination of their blood pressure elevating, glucose intolerance inducing, and procoagulant effects, 83, 84 as well as unfavourable effects on plasma lipoprotein profiles (HDL and LDL cholesterol). 85 Mean triglyceride levels were higher among current users of OCs. 84 When the effect of OCs on blood pressure and serum total cholesterol was measured in 14 to 24year-old young women, 85 those on the pill exhibited a significantly higher total cholesterol levels than controls. Because of the risk of OC-induced hypercholesterolaemia, even among adolescents; it is recommended that women and girls with family histories of premature heart disease have lipid analysis before taking OCs. 74
Stroke and oral contraceptives
While stroke is rarely seen in women of childbearing age, the association between high-oestrogen OCs content and increased risk of ischaemic stroke and venous thromboembolism has been documented in a number of studies. [86] [87] [88] Low-oestrogen OCs, on the other hand, do not appear to carry the same risk and are generally considered safe with regard to stroke. 89 The rarity of stroke in a large study of 15 to 44 yearold women in northern and southern California Kaiser Permanente Medical Care Programs taking OCs 89 was attributed to the low oestrogen content of the OCs (those in wide use in the United States have 30 or 35 g of oestrogen), and the fact that OC use in the United States is limited to women who do not have cardiovascular disease risk factors, including hypertension or diabetes.
The lower stroke risk with low-oestrogen OCs, was also documented in a study of 20 to 44-yearold OC users from Africa, Asia, Europe and Latin America conducted by the WHO Collaborative
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Study of Cardiovascular Disease and Steroid Hormone Contraception. 90 This group attributed the rarity of first stroke to the lower doses of oestrogen and progestagen, and stated that risk can be further reduced if the women are under 35 years of age, nonsmokers, have no history of hypertension, and have their blood pressure measured at the start of OC use. The type of progestogen was considered to contribute to the risk of arterial vascular disease in a number of studies in Great Britain in the 1970s and early 1980s. 91, 92 Esogestrel and gestodene were found to increase risk of venous thromboembolism in a World Health Organization Collaborative Study (WHO Collaborative Study 1996). 90 Oestrogen was reported to raise risk of stroke in a dose-dependent manner. 93 Several studies have stressed the importance of associated risk factors in the evaluation of the risk of stroke in OC users. According to the Collaborative Group for the Study of Stroke in Young Women, 88 the likelihood of stroke increases when OC use is accompanied by regular cigarette smoking, symptoms pointing to migraine, and/or hypertension.
Smoking was suggested to predispose certain OC users to immunologic vasculopathy, 94 and to induce significant procoagulant changes in prothrombin time and fibrinogen antigen. 95 Reduced sensitivity to activated protein C, which could increase the risk of thrombosis, was found in women using OCs. 96 Women with migraine were found to be prone to thrombotic stroke when taking OCs. 88 Thirty percent of women with cerebral infarction in a study by Hilton-Jones and Warlow 97 were found to be OC users; 15% of the patients had a history of migraine. In a study of women with first stroke, Haapaniemi et al 98 found OC use to be an independent risk factor for ischaemic brain infarction. Among 15 to 44-yearold OC users who had had a cerebral thromboembolic attack studied by Lidegaard 99 during a 5-year period in Denmark, the risk of stroke was six times greater among diabetic women who had had previous thrombotic disease, and three times greater among women with hypertension or migraine. Thus, women with multiple concomitant cardiovascular risk factors should be carefully screened and monitored prior to and during OC use.
Blood pressure in pregnancy
According to the classification scheme developed by the American College of Obstetricians and Gynecologists (ACOG) Committee on Terminology and endorsed by the US National High Blood Pressure Education Program (NHBPEP), high blood pressure in pregnancy is divided into four categories: chronic hypertension (essential or secondary), pre-eclampsia-eclampsia, pre-eclampsia superimposed on chronic hypertension and transient hypertension of pregnancy. 100, 101 These conditions have distinct pathophysiologies and prognoses and very different treatment requirements. However, they may be extremely difficult to diagnose on clinical grounds only. For this reason, and because hypertension in pregnancy may be life-threatening to both mother and fetus, referral to specialty care is recommended for all such patients. This topic has been reviewed thoroughly in this issue by Broughton-Pipkin and Roberts and will not be discussed further here.
Gender and awareness, treatment and control of high blood pressure
Women are more likely than men to be aware that they are hypertensive, to be receiving antihypertensive treatment, and to have their blood pressure controlled. In the large National Health and Nutrition Examination Survey (NHANES III) in the US, approximately 75% of non-Hispanic black and white women were aware of their high blood pressure, while only 65% of men in these groups were so informed. 9 Similarly, 61% of hypertensive women, but only 44% of men, were being treated with medication. This gender difference held across major ethnic groups. Finally, 28% of women overall and 19% of men had their blood pressure controlled (Ͻ140/90 mm Hg). In developed countries worldwide, hypertensive women have been reported to be 1.33-fold (95% CI = 1.32-1.34) more likely to be treated with antihypertensive drugs than are hypertensive men. 18 On average, 66% of hypertensive women but only 48% of hypertensive men were receiving antihypertensive drugs. The sex difference was greatest in the former USSR, where twice as many women as men were treated for hypertension. The higher antihypertensive treatment rates in women have been attributed to increased numbers of physician contacts because of visits for reproductive health and child care, as well as a lower probability of employment outside the home. There is clearly room for improvement, but it is encouraging that women are attentive to their own health needs in the area of hypertension and blood pressure control. This finding bodes well for the future cardiovascular health of women in the aging population.
Clinical trials of antihypertensive treatment in women
Women, like men, suffer from cardiovascular complications of hypertension, and their lives are shortened if blood pressure is not adequately controlled. The ultimate goal of antihypertensive treatment in women is the prevention of cardiovascular morbidity and mortality. None of the large multicentre trials of antihypertensive therapy with 'hard' endpoints have included enough women to analyse data from gender subgroups convincingly. Subgroup analyses from individual trials have yielded variable results regarding the risk/benefit ratio of pharmacological treatment of hypertension in women leading some to conclude that women derive less benefit than men from antihypertensive treatment.
A subgroup meta-analysis of individual patient data according to sex based on seven trials from the INDANA (INdividual Data ANalysis of Antihypertensive intervention trials) database was carried out in order to assess treatment effect by sex and determine whether there are gender differences. 102 These trials included 20 802 women and 19 975 men recruited between 1972 and 1990 and treated with thiazide diuretics and/or beta-blockers. In women, significant treatment benefits included reductions in strokes (total and fatal) and major cardiovascular events, while in men, treatment benefits were significant for all seven outcomes considered ( Table 2 ). In terms of relative risk, treatment benefits did not differ between the sexes. However, absolute risk reduction is dependent on untreated risk, and untreated risk for stroke was similar in the two sexes; for coronary events, was greater in men. Accordingly, absolute risk reduction for stroke attributed to treatment was similar in men and women; for coronary events, was greater in men.
These results cannot be extrapolated to the newer classes of antihypertensive drugs. Such a review is planned by the INDANA Group for ongoing prospective clinical trials. Nevertheless, since a major benefit of antihypertensive treatment is prevention of stroke, and the risk of stroke is similar in both sexes, it is reasonable to conclude that the sex of the patient should not play a role in decisions about whether or not to treat high blood pressure. 102 Whether the threshold for pharmacologic treatment of hypertension should be higher for young women (minor contributors to the INDANA study population) than for older women and men because of their low absolute cardiovascular risk is currently being debated.
Gender considerations in the choice of antihypertensive drugs
Currently, few data are available regarding the safety and efficacy of antihypertensive drugs in hypertensive postmenopausal women receiving hormone replacement. Further, no data are available on possible interactions between specific classes of antihypertensive drugs and postmenopausal hormones. Younger women of reproductive potential are excluded from most antihypertensive trials due to possible teratogenicity of these medications, and a low prevalence of hypertension. Older women are usually included in antihypertensive trials, but the results are seldom analysed with respect to the hormone status of the participants. This is a potentially fruitful area for further clinical trials and more extensive analysis of data from existing trials. In the interim, the collective results of existing trials should be extrapolated to postmenopausal women in general as well as those receiving hormone replacement therapy.
One small study by Koch et al 103 evaluated 95 postmenopausal, moderately hypertensive women (diastolic blood pressure between 95-114 mm Hg) receiving hormone replacement therapy. These women were randomised to receive either placebo or the angiotensin-converting enzyme (ACE) inhibitor moexipril 15 mg daily. After 12 weeks of followup, moexipril reduced systolic and diastolic blood pressure to a significantly greater extent than placebo. This small study provides limited information on long-term control of blood pressure in hypertensive women receiving hormone replacement but, it would seem to indicate that an ACE inhibitor is effective at reducing blood pressure in this target group. Current therapeutic recommendations for hypertension are not specific for gender and/or hormone status. However, some special considerations may dictate antihypertensive treatment choices for women. Most importantly, ACE inhibitors and AT 1 receptor blockers are contraindicated for women who are or intend to become pregnant because of the risk of fetal development abnormalities. Betaadrenergic blockers tend to be less effective than in men. 104 Diuretics are particularly useful in women, particularly elderly women, because their use is associated with decreased bone loss and reduced risk of hip fracture. 105 Diuretics are the favourite antihypertensive drug class for the treatment of women throughout the world, while beta-blockers, ACE inhibitors and calcium channel blockers are more often prescribed for men. Women tend to report more symptoms related to both their hypertension and their antihypertensive drugs, so treatment choices may depend more on adverse effect profile than on efficacy of a particular agent.
A growing body of evidence suggests that antihypertensive drugs have gender specific side effect profiles. For example, in the Treatment of Mild Hypertension Study (TOMHS), in which 902 men and women received nonpharmacological treatment with a drug from each class of antihypertensive agent, women reported twice as many side effects as men. 106 The incidence of side effects in women was similar in placebo-and drug-treated individuals. Biochemical responses to drugs may be gender dependent: women are more likely to develop hyponatraemia associated with diuretic therapy, whereas men are more likely to develop gout. 107 Hypokalaemia is more common in women taking diuretic. 107 ACE inhibitor-induced cough is twice as common in women as in men, 108 and bothersome calcium channel blocker oedema is much more common in women than men, as is unacceptable minoxidil-induced hirsuitism.
Preliminary evidence suggests that menopausal status may influence the effect of drugs on lipid profiles: large doses of diuretics have been shown to Journal of Human Hypertension raise total cholesterol in men and postmenopausal, but not premenopausal women. The effect of antihypertensive therapy on sexual function is a major obstacle to successful therapy of hypertension in men, and there is evidence that sexual dysfunction is a problem in hypertensive women as well. 107 However, information regarding sexual dysfunction in women is seldom obtained in clinical trials or in clinical practice. This is an area clearly in need of further investigation. With the caveats indicated, the guidelines for the diagnosis and treatment of hypertension in women are not gender-specific (JNC VI, and WHO-ISH). 109, 110 Further research on both basic science and clinical/population science levels should yield new insights that guide the prevention and care of hypertension in women.
